Downtown Los Angeles, California
Officially Endorsed by:
THE HEART FAILURE SOCIETY OF AMERICA
CALIFORNIA CHAPTER OF THE
AMERICAN COLLEGE OF CARDIOLOGY
INTERNATIONAL ACADEMY OF CARDIOLOGY
Update on Diagnosis and Therapy
August 1, 2020
IMPORTANT CME CREDIT NOTICE
CME Certificates will be issued digitally after Speaker and Symposium Surveys are completed.
Surveys are accessible after signing in with the email address you submitted during registration.
Surveys will be accessible online the day of the symposium and for 3 weeks following. You must complete the process by August 24, 2020 in order to receive your certificate. Certificates will be available online until April 1, 2021 and are printable directly from the website.
This Live activity, 24th Annual Heart Failure 2020: An Update on Therapy , with a beginning date of 08/01/2020, has been reviewed and is acceptable for up to 5.75 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award.
AANP: The American Academy of Nurse Practitioners accepts AAFP Prescribed credit. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
ANCC: According to the ANCC, the continuing education hours approved by the AAFP meet the ANCC-accredited CNE criteria.
AAPA: The American Academy of Physician Assistants accepts AAFP Prescribed credit for AAPA Category 1 CME credit.
This year’s program provides a comprehensive update on the prevention, diagnosis and management of heart failure (HF). The program includes lectures presented by experts combined with interactive discussion with faculty. The extensive list of topics has been selected to provide a high level, contemporary and clinically relevant update with a goal of improving the care of patients with heart failure.
At the conclusion of this activity, the participants should be able to:
- Review recent guidelines for the management of HF
- Manage volume overload in hospitalized patients with HF and review new
recommendations for the use of diuretics
- Manage diabetes in patients with HF
- Develop a step wide approach to early diagnosis and management of
- Use new therapy for the management of hyperkalemia in patients with HF
- Understand the relationship between HF and atrial fibrillation
- Understand treatment options for the prevention of sudden death in HF
- Provide an update on the diagnosis and management of HF due to myocarditis
- Understand the role of the right ventricle in the prognosis and management of HF
- Understand the role of endomyocardial biopsy in the diagnosis of HF etiology
- Provide a perspective on the Swan-Ganz Catheter
- Review the innovations in the area of ventricular assist devices in the
management of advanced HF
- Review the differences between the various bedside mechanical assist devices
in the prevention and management of cardiogenic shock
- Understand the continuing role of heart transplantation in the treatment of
- Understand the indication and effect of iron supplements in patients with HF
- Learn how to use high sensitivity troponin for the diagnosis and prognosis of
patients with HF
- Provide an update on new therapeutic approaches for the management of
patients with chronic HF
This program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.
Heart failure (HF) is common, but often unrecognized and misdiagnosed. Early diagnosis and effective therapy is important (Circulation 2013;128:e240). There is strong evidence that increased use of evidence based, life sustaining therapies and performance measures have a significant impact on the outcome of patients with HF (BMC CV Disorders 2016;16:195). Recent data continues to show an important gap between published guideline recommendations and practice (Eur J HF 2017;19:301) and demonstrates that life-saving drugs and devices are underutilized (Circulation 2016;133:273, JAMA Cardiol 2017;2561, JACC 2016; 67:1062) and indicates the need for education and incorporation of recent guidelines by clinicians (Circulation 2017;136: e137). The Heart Failure 2020 symposium has been designed to provide an update on new diagnostic and therapeutic modalities as well as new practice guidelines for the management of patients with HF.
It is our policy to ensure balance, independence, objectivity and scientific
rigor. All persons involved in the selection, development and presentation
of content are required to disclose any real or apparent conflicts of
interest. All conflicts of interest will be resolved prior to an educational
activity being delivered to learners through one of the following mechanisms
1) altering the financial relationship with the commercial interest, 2)
altering the individual’s control over CME content about the products
or services of the commercial interest, and/or 3) validating the activity
content through independent peer review. All persons are also required
to disclose any discussions of off label/unapproved uses of drugs or devices.
Persons who refuse or fail to disclose are disqualified from participating
in the CME activity. Participants will be asked to evaluate whether the
speaker’s outside interests reflect a possible bias in the planning
or presentation of the activity. This information is used to plan future